skip to content


4D pharma delays dosing for Thetanix trial

26 February 2016 09:20

4D pharma has decided to delay dosing for the phase 1 trial of Thetanix, its proprietary programme for the treatment of Paediatric Crohn's Disease, which was scheduled to begin on 1 March.

It says this is because concerns have come to light at one of its supply partners during manufacture of an additional batch of Thetanix. The decision to delay was taken as a precautionary measure.

The company says it is working to resolve this issue and dosing of patients is anticipated to commence after an investigation has taken place. This is anticipated to take around one month.

The company says recruitment for the phase 1 trial of Blautix, its proprietary programme for the treatment of Irritable Bowel Syndrome, has now been completed. It is hoped that further data from the trial, involving 56 healthy volunteers and IBS patients, will be available in April.

Chief scientific officer Dr. Alex Stevenson said: "Although we are eager to progress our phase 1 trial in Paediatric Crohn's Disease, we have taken the precautionary measure of delaying the dosing of patients until our investigation has been completed. Importantly all our other programmes are unaffected by this issue, and we remain on track to deliver new programmes into the clinic in 2016. Further, we are pleased to be able to report the completion of patient recruitment in the Blautix phase 1 trial, and we look forward to reporting further results of the trial over the coming weeks."

At 9:20am: (LON:DDDD) 4d Pharma Plc Ord 0.25p share price was -12.5p at 920p

Story provided by

Related Company: DDDD

Info Point:

To buy or sell shares call our Dealing Room on 0113 243 6941.

Too much jargon? Our glossary will help make sense of things.

Find out more about our Share Dealing Services.

Client Area Access

» Secure Login

» Not registered yet?

Bluezest Aviva Aberdeen

Branch Finder

Redmayne-Bentley have High Street branches throughout the UK. Find your nearest branch.